Indeed, 5-FU based chemotherapy is a mainstay of CRC treatment [14, 28–30] and ectopic expression of RPL22L1 enhances 5-FU resistance, which is associated with both increased MGMT expression and decreased expression of the MMR gene, MLH1. Here, MLH1 is linked to colorectal carcinoma.